,
8 tweets,
5 min read
Read on Twitter
Prevention & Treatment of #DKD
@cellotonelli
Health in All Policies (HiAP)
Systematically considering the health effects of all policies.
Big problems need big solutions.
SGLT2i are a part of the solution that we need 5 lenses:
Benefits
Harms
Utilization
Value
Access
@cellotonelli
Health in All Policies (HiAP)
Systematically considering the health effects of all policies.
Big problems need big solutions.
SGLT2i are a part of the solution that we need 5 lenses:
Benefits
Harms
Utilization
Value
Access
Changing Landscape: Advances in Understanding DKD Pathophysiology
Kathy Tuttle
Dual specialist who sees more people with diabetes in the nephrology clinic than in the endocrine clinic!
SGLT2i of course &
GLP1 receptor antagonists kidney outcomes data reviewed
Kathy Tuttle
Dual specialist who sees more people with diabetes in the nephrology clinic than in the endocrine clinic!
SGLT2i of course &
GLP1 receptor antagonists kidney outcomes data reviewed
SGLT2i & the CV system
Darren McGuire
HF ⬇️risk is independent of ASCVD, baseline A1c and observed across eGFR levels.
HF ⬇️risk is greater in HFrEF than HFpEF.
⬆️Hb is more related to
⬆️ erythropoietin at 2-4 weeks than to hemoconcentration.
bit.ly/2Xevid1
Darren McGuire
HF ⬇️risk is independent of ASCVD, baseline A1c and observed across eGFR levels.
HF ⬇️risk is greater in HFrEF than HFpEF.
⬆️Hb is more related to
⬆️ erythropoietin at 2-4 weeks than to hemoconcentration.
bit.ly/2Xevid1
Overview of available data evaluating SGLT2i in T2DM & CKD
@jardine_meg
⬇️ progression down to eGFR 30, esp. in those with albuminuria
Prevent kidney failure
⬇️ HF & CV events
Meta-analysis results driven by #CREDENCE
Increased use of SGLT2i should be an urgent priority
@jardine_meg
⬇️ progression down to eGFR 30, esp. in those with albuminuria
Prevent kidney failure
⬇️ HF & CV events
Meta-analysis results driven by #CREDENCE
Increased use of SGLT2i should be an urgent priority
Review of Ongoing Studies Evaluating SGLT2i in Kidney and Cardiovascular Disease
Hiddo Lambers Heerspink
Impressive number of ongoing studies reviewed, including two that are enrolling CKD with and without diabetes.
DAPA-CKD
EMPA-Kidney
Hiddo Lambers Heerspink
Impressive number of ongoing studies reviewed, including two that are enrolling CKD with and without diabetes.
DAPA-CKD
EMPA-Kidney
Metabolic Effects of SGLTi:
The Good & the Bad
Merlin Thomas
What should we know about DKA?
Rare in T2DM, but severe & important to Dx as euglycemia may delay recognition.
Assoc w intercurrent illness & insulin Tx
Prevention
Hold drug periop
UK sick day rules?
The Good & the Bad
Merlin Thomas
What should we know about DKA?
Rare in T2DM, but severe & important to Dx as euglycemia may delay recognition.
Assoc w intercurrent illness & insulin Tx
Prevention
Hold drug periop
UK sick day rules?
An incredible group led by Kathy Tuttle & @VladoPerkovic
Breakouts:
1 Mechanisms of SGLT2i in Kidney & CV Diseases
2 Effects of SGLT2i on the Onset & Progression of CKD
3 Effects of SGLT2i on CV Diseases & Other Outcomes
4 Integration of SGLT2i into Clinical Practice
@NKF
Breakouts:
1 Mechanisms of SGLT2i in Kidney & CV Diseases
2 Effects of SGLT2i on the Onset & Progression of CKD
3 Effects of SGLT2i on CV Diseases & Other Outcomes
4 Integration of SGLT2i into Clinical Practice
@NKF
